← Eichor
Study identifier: NCT06596746 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Condition: Neurodegenerative Diseases · Parkinson Disease · Synucleinopathies  ·  Sponsor: Casa di Cura San Raffaele Cassino

PhaseN/A
Planned participants600
Who can joinAll sexes, 10 Years to no upper limit
Healthy volunteersNo

About this study

MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Maria Francesca De Pandis, MD, PhD, Neurologist  ·  0776394740  ·  maria.depandis@sanraffaele.it

Maria Gaglione  ·  0776394740  ·  maria.gaglione@sanraffaele.it

Always discuss trial participation with your own doctor first.

Locations (1)

San Raffaele CassinoCassino, Frosinone, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06596746